bioMerieux Opens a Subsidiary in the Middle East, Continuing its International Growth
bioMérieux announced the opening of a subsidiary in the United Arab Emirates. A hub for its operations in the Middle East, bioMérieux’s 39th subsidiary will be based in Dubai. Active in the region for more than 25 years, bioMérieux has established a leading position in the United Arab Emirates diagnostics market, according to the company, through its exclusive distributor, Al Hayat Pharmaceuticals, with whom it will continue to work closely.
"This new subsidiary will be the hub for our Middle East commercial team. With 20,000 healthcare professionals in Dubai HealthCare City and international centers of excellence such as Harvard Medical School and Mayo Clinic, there are exciting opportunities in the UAE health economy," said Stéphane Bancel, Chief Executive Officer of bioMérieux. "bioMérieux’s solid business model allows us to continue our international expansion, a key factor for future growth and sales diversification."
Dubai HealthCare City, where the bioMérieux subsidiary is located, has the ambition of becoming the leading center in the region, filling a gap in healthcare services in the zone between Europe and Southeast Asia. bioMérieux will bring, in particular, its expertise as a world leader in diagnostics for healthcare associated infections (HAI) to local hospitals and universities to build HAI management programs.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C

Analytica 2022: Fighting COVID-19 with combined expertise - New tools in virus research and detection

Obulytix is developing a revolutionary solution for antibiotic resistance - Spin-off has built a platform that creates new ways to tackle bacterial infections
Sarcospan, a little protein for a big problem
Ribosome
Blood_alcohol_content
UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

Novel spatial-omics technology enables investigation of diseases at their early stages - How can you trace a single diseased cell in an intact brain or a human heart?
A long day for microbes, and the rise of oxygen on Earth
